Bangalore, Oct 16 (UNI) Biotech giant Biocon has sustained growth with its revenue touching Rs 734 crore (including AxiCorp), an upward growth of 33 per cent compared to the previous half, during the half year (H1) ending September 30 of the fiscal year 2008-09.
During the corresponding period previous year the company's revenue was Rs 553 crore (excluding AxiCorp).
Releasing the company's half-yearly report here today, Biocon CEO and Managing Director Kiran Majumdar Shaw told newspersons that the Pharma sales (excluding licensing income and Axicorp) has registered a 21 per cent growth bolstered by a 36 per cent growth in retail healthcare business.
She said,''the first half-yearly performance has shown resilience despite being impacted by rupee volatility, which has seen us make a mark to market provision of Rs 60 crore''.
''At a time when global business are challenged with an economic downturn, we believe that our strong financial base gives us a significant advantage. Second quarter (Q2) of the current fiscal has seen us deliver the highest ever revenues across all divisions,'' she added.
UNI MSP MV MDG 1839